Research and Clinical Trials on Clonazepam (Klonopin, Rivotril)

Clonazepam (Klonopin, Rivotril) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Clonazepam (Klonopin, Rivotril).

• Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
  Status: Recruiting, Condition Summary: REM Behavior Disorder; Parkinsonism
• Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population
  Status: Completed, Condition Summary: Pharmacokinetics
• Deanxit and Rivotril in Tinnitus Patients
  Status: Completed, Condition Summary: Tinnitus
• Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
  Status: Completed, Condition Summary: Schizophrenia
• Therapies for Treatment-Resistant Panic Disorder Symptoms
  Status: Completed, Condition Summary: Panic Disorder
• Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
  Status: Completed, Condition Summary: Epilepsy
• Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
  Status: Active, not recruiting, Condition Summary: Epilepsy; Mental Retardation
• Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
  Status: Recruiting, Condition Summary: Social Phobia
• Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)
  Status: Completed, Condition Summary: Cramps; Amyotrophic Lateral Sclerosis
• Bioavailability Study of Clonazepam Tablets Under Fasting Conditions
  Status: Completed, Condition Summary: To Determine Bioequivalence Under Fasting Conditions
• Bioavailability Study of Clonazepam ODT Under Fasting Conditions
  Status: Completed, Condition Summary: To Determine Bioequivalence Under Fasting Conditions
• Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type
  Status: Enrolling by invitation, Condition Summary: Unverricht-Lundborg Syndrome
• Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder
  Status: Completed, Condition Summary: Post Traumatic Stress Disorder
• Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression
  Status: Completed, Condition Summary: Panic Disorder
• Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus
  Status: Recruiting, Condition Summary: Status Epilepticus

 

Get These Clinical Trials as a Newsfeed

Clonazepam:             

Current Research Literature on Clonazepam (Klonopin, Rivotril)

Here are abstracts for some of the latest research articles to have appeared on Clonazepam (Klonopin, Rivotril):

Allosteric modulation by benzodiazepines of GABA-gated chloride channels of an identified insect motor neurone.

Invert Neurosci. 2009 Oct 22;
Buckingham SD, Higashino Y, Sattelle DB
The actions of benzodiazepines were studied on the responses to GABA of the fast coxal depressor (D(f)) motor neurone of the cockroach, Periplaneta americana. Ro5-4864, diazepam and clonazepam were investigated. Responses to GABA receptors were enhanced by both Ro5-4864 and diazepam, whereas clonazepam, a potent-positive allosteric modulator of human GABA(A) receptors, was ineffective on the native insect GABA receptors of the D(f) motor neurone. Thus, clear pharmacological differences exist between insect and mammalian native GABA-gated chloride channels with respect to the actions of benzodiazepines. The results enhance our understanding of invertebrate GABA-gated chloride channels which have recently proved important in (a) comparative studies aimed at identifying human allosteric drug-binding sites and (b) understanding the actions of compounds used to control ectoparasites and insect crop pests.

Sleep-related breathing and sleep-wake disturbances in ischemic stroke.

Neurology. 2009 Oct 20; 73(16): 1313-22
Hermann DM, Bassetti CL
BACKGROUND: Sleep-related breathing disturbances (SDB) and sleep-wake disturbances (SWD) are often neglected in stroke patients. Recent studies suggest that they are frequent and have an impact on stroke outcome. METHODS: We review current knowledge about frequency, clinical presentation, and consequences of poststroke SDB and SWD, and discuss treatment options. RESULTS: SDB, presenting with obstructive, central, or mixed apneas, is present in 50%-70% of stroke patients. We recommend screening for SDB in all stroke patients by respirography. Continuous positive airway pressure (CPAP) is the treatment of choice for obstructive SDB, which reverses the vascular risk of the patients. In the absence of controlled trials, CPAP treatment should be reserved for patients with severe obstructive SDB, daytime symptoms (e.g., sleepiness), or high cardiovascular risk profile. Oxygen and adaptive servoventilation may be used for central SDB. SWD including insomnia, disturbances of wakefulness (hypersomnia, excessive daytime sleepiness, fatigue), sleep-related movement disorders (restless legs syndrome, periodic limb movements during sleep), and parasomnias (REM sleep behavior disorder) are found in 10%-50% of patients. SWD are associated with cognitive disturbances and may compromise neurologic recovery. Hypnotics and sedative antidepressants may aggravate SDB and neurologic recovery and should be used with caution. For disturbances of wakefulness, dopaminergic drugs, modafinil, or activating antidepressants may be considered. Poststroke sleep-related movement disorders can be treated with dopaminergic drugs; REM sleep behavior disorder with clonazepam. CONCLUSIONS: Sleep-related breathing disturbances and sleep-wake disturbances are frequent conditions that affect stroke outcome. In view of existing treatment options, these conditions deserve the neurologist's awareness.

Population-based study of antiepileptic drug exposure in utero-Influence on head circumference in newborns.

Seizure. 2009 Oct 12;
Almgren M, Källén B, Lavebratt C
PURPOSE: To study the effect of AED exposure on head circumference in the newborn. METHODS: Data on all Swedish singletons births between 1995 and 2005, over 900,000 births, were obtained from the Swedish Medical Birth Registry. The effects of AEDs on birth-weight-adjusted mean head circumference (bw-adj-HC) were estimated by comparison with data from all births in an analysis which was adjusted for year of birth, maternal age, parity, maternal smoking, and maternal body mass index. RESULTS: A significant reduction of mean bw-adj-HC was seen after both carbamazepine (CBZ) (standard deviation scores (SDS)=0.15, p

Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E.

Indian J Psychiatry. 2009 Apr; 51(2): 162-3
Sharma H

Estimation of clonazepam abuse liability: a new method using a reimbursed drug database.

Int Clin Psychopharmacol. 2009 Nov; 24(6): 318-24
Frauger E, Pauly V, Thirion X, Natali F, Pradel V, Reggio P, Rouby F, Coudert H, Micallef J
Some observations suggest the existence of clonazepam abuse. The aim of this study was to assess its magnitude in real life by a new method, using a prescription database, and to assess its evolution between 2001 and 2006. Individuals from a region affiliated to the French health reimbursement system, who had a prescription of clonazepam reimbursed between 1 January and 15 February of two selected years were included. Their deliveries were monitored over a 9-month period. After a descriptive analysis, a clustering method illustrated by a factorial analysis was used to identify different subgroups of clonazepam consumers. An increase of 82% in participants who had a delivery of clonazepam between 2001 and 2006 was observed. Using the clustering method, this study identified some deviant participants. This group comprises a higher proportion of males, benzodiazepine users, and buprenorphine users. The number of deliveries by different prescribers and pharmacies are higher. The proportion of deviant participants increased between 2001 and 2006 (from 0.86 to 1.38%). Our method can be used to assess the magnitude of abuse liability of clonazepam and is also interesting for following its evolution, two important keys for assessing patterns of abuse.